Breakdown | |||||
TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
207.18B | 192.99B | 176.92B | 168.53B | 163.56B | 132.64B | Gross Profit |
49.99B | 45.69B | 43.35B | 42.31B | 41.84B | 34.23B | EBIT |
7.00B | 6.92B | 6.50B | 7.45B | 7.06B | 5.78B | EBITDA |
9.63B | 9.67B | 8.48B | 9.36B | 8.75B | 7.29B | Net Income Common Stockholders |
4.89B | 5.17B | 3.82B | 5.25B | 4.86B | 3.52B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
15.29B | 17.14B | 15.69B | 17.03B | 16.26B | 16.46B | Total Assets |
70.91B | 61.87B | 57.20B | 54.15B | 51.39B | 47.89B | Total Debt |
14.07B | 9.17B | 9.30B | 9.30B | 9.30B | 9.35B | Net Debt |
-1.22B | -7.97B | -6.39B | -7.73B | -6.96B | -7.12B | Total Liabilities |
39.28B | 31.90B | 30.45B | 29.40B | 30.13B | 25.87B | Stockholders Equity |
31.62B | 29.97B | 26.76B | 24.59B | 21.10B | 21.98B |
Cash Flow | Free Cash Flow | ||||
0.00 | 3.52B | 1.29B | 2.76B | 6.72B | 3.25B | Operating Cash Flow |
0.00 | 7.39B | 3.96B | 5.63B | 9.31B | 5.06B | Investing Cash Flow |
0.00 | -4.00B | -3.31B | -3.25B | -2.97B | -2.62B | Financing Cash Flow |
0.00 | -1.94B | -2.00B | -1.62B | -6.55B | -506.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | ¥60.10B | 11.78 | 1.72% | 13.93% | -11.16% | ||
77 Outperform | ¥102.31B | 10.92 | 2.18% | 2.91% | 12.82% | ||
77 Outperform | ¥62.25B | 11.53 | 1.80% | 6.47% | 10.56% | ||
74 Outperform | ¥104.42B | 11.70 | 1.23% | 7.83% | 3.68% | ||
71 Outperform | ¥58.93B | 11.04 | 2.83% | 5.78% | 10.78% | ||
69 Neutral | ¥59.41B | 11.96 | 2.97% | 10.95% | -3.96% | ||
65 Neutral | $8.89B | 15.01 | 4.75% | 203.76% | 3.54% | -2.49% |
G-7 Holdings Inc. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing an 11% increase in net sales to ¥214,129 million. Despite this growth, profit attributable to owners of the parent decreased by 4.6% to ¥4,939 million. The company anticipates further growth in the next fiscal year, forecasting a 7.4% increase in net sales and a 15.4% rise in profit attributable to owners. The inclusion of Bonne Sante Co., Ltd. in its consolidation scope marks a strategic expansion, potentially enhancing its market position and offering new opportunities for stakeholders.